Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
20.05%
Operating Margin
71.09%
Net Margin
16.56%
Efficiency Metrics
Revenue per Expense Ratio
4.99
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
0.00%
Income Tax Rate
-9.54%
EPS
0.8000000000
Balance Sheet Analysis
Current Ratio
0.31
Cash Ratio
0.26
Working Capital
$-68.34B
Debt to Equity
1.80
Debt to Assets
63.41%
Equity Ratio
35.23%
Cash Flow Analysis
Operating Cash Flow Ratio
-16.31%
Free Cash Flow Ratio
-16.31%
CapEx to Revenue
0.00%
Dividends Paid
$35.53M
Stock Buybacks
$943.25K
Total Shareholder Returns
$36.47M
Cash Position Change
-45.62%
Key Takeaways (2023 FY)
Maintained positive net income growth despite revenue changes
Increased dividend payments by 18.71%
Detailed Growth Metrics
Core Performance
Revenue
405.24%
Net Income
20.99%
EPS
8.11%
Operating Income
38.79%
Operational Efficiency
R&D Expenses
-100.00%
SG&A Expenses
8.73%
Operating Cash Flow
69.33%
Free Cash Flow
69.33%
Balance Sheet Health
Assets
1.10%
Debt
-4.68%
Book Value per Share
3.09%
Inventory
-100.08%
Shareholder Returns
Dividends per Share
18.71%
Shares Outstanding
12.54%
Long Term Trends
3Y Revenue/Share
261.89%
5Y Revenue/Share
147.10%
3Y Dividend/Share
29.15%
5Y Dividend/Share
19.28%